AFX Medical's aspiring AI technology transforms brain lesion detection in radiation oncology
Yesterday, (April 29), during a packed program of events, OSP was invited to watch presentations from four startups nurtured by Centech, that are reaching a critical stage in their projects. In a series of articles, these will be covered as part of several interviews, presentations, and visits, OSP was lucky enough to attend and cover.
The first of this miniseries is the substantial leap forward for radiation oncology, startup AFX Medical has introduced, which is an innovative AI-driven solution aimed at revolutionizing the detection and measurement of brain lesions during radiation therapy.
Sophie Pawlowski, head of partnerships at AFX Medical, described how the team she works with has developed cutting-edge technology that automates this critical process with significant accuracy, promising to enhance the efficacy of radiation oncology treatments.
Challenges faced by oncologists
Sophie provided insights into the challenges faced by radiation oncologists in detecting and measuring brain lesions during therapy sessions. She explained that traditional methods often rely on manual comparison of MRI scans, a process fraught with challenges due to the complexity of the human brain and the dynamic nature of lesions.
“Our mission is to empower radiation oncologists with advanced tools that streamline the treatment process and improve patient outcomes," she said.
“Our software harnesses the power of machine learning algorithms and computer vision to detect and measure brain lesions in real-time, providing clinicians with invaluable insights into individual lesions.”
Significant advancement in radiation oncology
The software developed by AFX Medical marks a significant advancement in the field of radiation oncology. Sophie highlighted its ability to sync and recognize identical MRI scans, enabling radiation oncologists to track lesions with unprecedented precision over multiple treatment sessions. This capability not only enhances the accuracy of treatment planning but also allows clinicians to monitor changes in lesion size and growth rates, facilitating informed decisions regarding the need for retreatment.
“We understand the importance of collaboration and teamwork in driving innovation,” Sophie emphasized. “Our team is dedicated to continually improving the accuracy and functionality of our software to meet the evolving needs of radiation oncologists and their patients.”
The introduction of AFX Medical's AI-powered medical imaging software, she says, has been met with enthusiasm and optimism within the radiation oncology community. This Sophie says shows the importance of the transformative potential of this technology in improving the delivery of radiation therapy for patients with brain metastases.
“As radiation oncologists, our ultimate goal is to provide the best possible care for our patients,” Sophie explained. “By leveraging AI technology to enhance lesion detection and measurement, we can optimize treatment strategies and improve outcomes for individuals undergoing radiation therapy.”
Tracking brain metastases
Looking ahead, AFX Medical remains committed to advancing the field of radiation oncology through continued innovation and collaboration. Sophie outlined several action items aimed at further enhancing the software's detection accuracy, gathering feedback from partner hospitals, and tracking brain metastases over multiple treatments to inform clinical decision-making.
“Innovation is at the heart of everything we do at AFX Medical. We are excited to continue pushing the boundaries of technology to transform the landscape of radiation oncology and make a positive impact on the lives of patients worldwide.”
As AFX Medical continues to spearhead advancements in AI-driven healthcare solutions, the future of radiation oncology is progressing, showing promise for improved outcomes and enhanced quality of care for patients battling brain metastases.
